text_1: 我们 发现 , 在 新 诊断 出 晚期 卵巢癌 , 并且 对 铂 类 化疗 产生 应答 的 患者 中 , 每日 口服 PARP 抑制剂 尼 拉帕 利后 的 无 进展 生存期 显著 超过 口服 安慰剂 后 .
  
text_2: we found that among patients with newly diagnosed advanced ovarian cancer , those who received daily oral therapy with the PARP inhibitor niraparib after a response to platinum @-@ based chemotherapy had a significantly longer duration of progression @-@ free survival than those who received placebo .
  